Nisa Investment Advisors LLC Buys 17,160 Shares of Boston Scientific Corporation (NYSE:BSX)

Nisa Investment Advisors LLC boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 405,955 shares of the medical equipment provider's stock after purchasing an additional 17,160 shares during the quarter. Nisa Investment Advisors LLC's holdings in Boston Scientific were worth $40,953,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Axxcess Wealth Management LLC grew its holdings in shares of Boston Scientific by 13.7% during the first quarter. Axxcess Wealth Management LLC now owns 10,228 shares of the medical equipment provider's stock worth $1,032,000 after purchasing an additional 1,234 shares during the last quarter. Rehmann Capital Advisory Group grew its holdings in shares of Boston Scientific by 6.1% during the first quarter. Rehmann Capital Advisory Group now owns 5,567 shares of the medical equipment provider's stock worth $562,000 after purchasing an additional 322 shares during the last quarter. Greenleaf Trust grew its holdings in shares of Boston Scientific by 6.3% during the first quarter. Greenleaf Trust now owns 28,258 shares of the medical equipment provider's stock worth $2,851,000 after purchasing an additional 1,665 shares during the last quarter. Trek Financial LLC grew its holdings in shares of Boston Scientific by 990.2% during the first quarter. Trek Financial LLC now owns 34,504 shares of the medical equipment provider's stock worth $3,481,000 after purchasing an additional 31,339 shares during the last quarter. Finally, Personal CFO Solutions LLC bought a new stake in shares of Boston Scientific during the first quarter worth about $219,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Up 1.3%

Shares of BSX stock traded up $1.31 on Thursday, hitting $104.27. The stock had a trading volume of 3,632,658 shares, compared to its average volume of 6,673,345. The business has a 50 day moving average of $103.45 and a 200 day moving average of $100.35. The stock has a market cap of $154.26 billion, a price-to-earnings ratio of 76.10, a price-to-earnings-growth ratio of 2.66 and a beta of 0.68. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88. Boston Scientific Corporation has a 12-month low of $71.88 and a 12-month high of $107.53.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.67 by $0.08. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.58% and a return on equity of 18.67%. The firm's revenue for the quarter was up 20.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.56 earnings per share. As a group, analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other news, SVP Vance R. Brown sold 4,826 shares of the firm's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the transaction, the senior vice president directly owned 36,193 shares in the company, valued at approximately $3,441,592.37. This trade represents a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,314 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the completion of the transaction, the executive vice president owned 22,235 shares of the company's stock, valued at $2,269,304.10. This trade represents a 43.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 461,970 shares of company stock valued at $47,755,193 in the last 90 days. 0.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BSX. Morgan Stanley boosted their price target on Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Wall Street Zen upgraded Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Royal Bank Of Canada boosted their price target on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Barclays boosted their price target on Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Twenty-two investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $116.09.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.